<DOC>
	<DOC>NCT01617005</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs. Data will be collected from each eligible participant initiating tocilizumab treatment over 6 months.</brief_summary>
	<brief_title>A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Moderate to severe active RA (European League Against Rheumatism [EULAR] criteria) Inadequate response to DMARDs or tumor necrosis factor (TNF) antagonists Initiating treatment with tocilizumab according to SPC Rheumatic autoimmune disease other than RA Prior history or current inflammatory joint disease other than RA Previous treatment with any biological drug used in the treatment of RA Previous treatment with tocilizumab Any contraindication to treatment with tocilizumab Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment Pregnant women or nursing (breastfeeding) mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>